the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
Published 1 month ago • 114 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
1:10:01
the nuclear pore and xpo1:guardian of the genome
-
17:46
expression platform for producing flexible and novel bispecific modalities at pandemic speed
-
4:29
bioivt your trusted adme partner, extended
-
2:56
the exciting future of bispecific antibodies
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
2:00
the success story of bispecific and trispecific antibodies
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
0:58
first-in-human trial of cln-978, a novel cd19 bispecific antibody, for the treatment of r/r b-nhl
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:09
outpatient dosing of bispecific antibodies: what do clinicians need to consider?
-
1:30
cardiovascular risk factors and pulmonary hypertension in patients with mpns